<DOC>
	<DOCNO>NCT00231751</DOCNO>
	<brief_summary>Existing data support concept genetic predisposition inhibitor development exists . The aim Malmö International Brother Study ( MIBS ) evaluate genetic factor associate development inhibitory antibody patient hemophilia .</brief_summary>
	<brief_title>The Malmö International Brother Study ( MIBS )</brief_title>
	<detailed_description>Inhibitory antibody factor VIII develop 10-15 % patient hemophilia A 25-30 % patient severe form disease exposure factor VIII concentrate . Both genetic environmental risk factor inhibitor development evaluate , case without consistent result . Among genetic factor , association large rearrangement factor VIII IX gene higher risk inhibitor describe . However , majority patient null mutation , include intron 22 inversion , develop inhibitory antibody . It obvious genetic marker influence immune response replacement therapy patient hemophilia remain identified aim Malmö International Brother Study ( MIBS ) characterize factor .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Mild , moderate severe hemophilia A B one brother mild , moderate severe hemophilia A B Absence sufficient information classify inhibitor status</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Inhibitors</keyword>
</DOC>